About AGB-Pharma
Our vision:
Better sleep health for everyone
AGB-Pharma works to improve treatment paths for any patient living with sleep disorders and to be the healthcare sector’s primary sleep health partner.
Sleep health
AGB-Pharma is an independent, Swedish, family-owned, pharmaceutical company that focuses on sleep health and specialises in the treatment of sleep disorders.
For us, good sleep health is more than just medication. Sleep is one of our fundamental needs. Anyone who’s ever slept badly or too little – particularly for an extended period of time – knows this. But poor sleep health is rarely a simple problem – and it’s often a problem for which there is no simple solution. We are, after all, talking about the entire person, not just synapses and neurotransmitters. Good sleep health is as much a matter of practical work and experience as it is science and theory. Which is why we believe in an ongoing, organised partnership in and with clinical reality. Because that is, after all, where we sleep.
AGB-Pharma manufactures and markets pharmaceuticals and has its head office located in the Swedish city of Lund, where it was founded in 2020. AGB-Pharma operates in Sweden, Norway, Denmark, the UK and Germany with production facilities in Scandinavia.
AGB-Pharma hopes, through an international expansion of its treatments for sleep disorders, to increase awareness of sleep disorders and the effect they have on people who suffer them.
For us, good sleep health is more than just medication. Sleep is one of our fundamental needs. Anyone who’s ever slept badly or too little – particularly for an extended period of time – knows this. But poor sleep health is rarely a simple problem – and it’s often a problem for which there is no simple solution. We are, after all, talking about the entire person, not just synapses and neurotransmitters. Good sleep health is as much a matter of practical work and experience as it is science and theory. Which is why we believe in an ongoing, organised partnership in and with clinical reality. Because that is, after all, where we sleep.
AGB-Pharma manufactures and markets pharmaceuticals and has its head office located in the Swedish city of Lund, where it was founded in 2020. AGB-Pharma operates in Sweden, Norway, Denmark, the UK and Germany with production facilities in Scandinavia.
AGB-Pharma hopes, through an international expansion of its treatments for sleep disorders, to increase awareness of sleep disorders and the effect they have on people who suffer them.
Markets
For more information about Melatonin AGB (Sweden), please see Product Information Leaflet on www.fass.se.
Safe, reliable production in Scandinavia
AGB-Pharma has its production in Scandinavia and the manufacturing process is EU-certified in accordance with GMP – Good Manufacturing Practice.
Active substance and necessary excipients are kept in large stock locally and the production is scalable to ensure the demand can always be met, thereby minimising the risk of delivery problems. Our products have never been backorder listed in Sweden.1
AGB-Pharma is an independent, Swedish, family-owned, pharmaceutical company whose head office is located in the Swedish city of Lund. The company’s operations focus on sleep health and treatments for sleep disorders.
Management group – Sweden
Karin Hesselgard, CEO
RN, PhD in neurosurgery
Karin was appointed as the CEO of AGB-Pharma in 2024 to lead and develop the company with a focus on profitability and long-term sustainable growth. Karin has 20 years of management experience at operational, tactical and strategic management level in complex organizations. Most recently, Karin has worked as a Senior Advisor in leadership and business development.
Karin has previous experience as Executive Director for Primary Care and Dentists in Region Halland and before that as Divisional Manager for Medical Technology and Prehospital Care as well as IT in Region Skåne. Karin has a PhD in neurosurgery with a focus on postoperative intrathecal pain treatment for children.
Lars Grundemar, Chief Medical Officer
MD, PhD, Professor of Clinical Pharmacology at Lund University
Lars has extensive experience of senior roles in global pharmaceutical development and in a wide range of therapeutic areas from Pfizer (Pharmacia), Novartis, AstraZeneca and other companies in Sweden, Italy, the USA, Switzerland, and Denmark. He has also been a Board Member of several life science companies in the pharmaceutical and biotech sectors, and was the CEO of the cancer pharmaceutical company, Oncorena.
Lars is an Adjunct Professor at the University of Lund, working with experimental and clinical pharmacology and pharmaceutical development. He has particular experience of experimental and clinical R&D of pharmaceuticals in the field of neurology, psychiatry, and pain.
Magnus Pålsson, Chief Commercial Officer
MBA, Heinrich-Heine-Universität Düsseldorf
Magnus has been the Chief Commercial Officer at AGB-Pharma since 2022 and was recruited from his position as the CEO of a leading, international diagnostics company in the field of women’s health.
Since graduating in Germany, Magnus has worked internationally in the life sciences sector (pharmaceuticals, health technology, and diagnostics), holding positions in both local subsidiary companies (Canada, Portugal, Sweden, and Switzerland) and global head offices (Germany, Sweden, and Finland).
Charlott Hall, Director Development and Operations
BSc in inorganic and analytical chemistry, University of Lund
Charlott took over the role of Director of Development and Operations at AGB-Pharma in 2021. The role entails responsibility for production, development, supply chain, and procurement and logistics.
Charlott has over 30 years’ experience of working in major pharmaceutical and health technology companies, including AstraZeneca, Pharmacia, Pfizer Consumer Healthcare and Gambro (subsequently Baxter.) She began her career as a laboratory engineer at AstraZeneca, since then she has worked as a research engineer, laboratory manager, and R&D Section Manager and Project Manager. Charlott has also worked in production as a Production Manager and Departmental Manager for Production Support.
Helena Eklöf, Director Regulatory, Quality Assurance and Pharmacovigilance
M.Sc. in Chemical Engineering, Faculty of Engineering (LTH), Lund University
Helena took over the role as Director of Regulatory, Quality Assurance and Pharmacovigilance in 2023 and has over 25 years’ experience of working in the pharmaceutical industry for such companies as Bioglan AB and Astra Zeneca. Helena joined AGB-Pharma from Ferring Läkemedel, where she had overall responsibility for RA, QA and PV for the Nordic marketing companies.
Fredrik Werner, Chief Financial Officer
Bachelor of Science in Economics, Lund University
Fredrik has served as the CFO of AGB-Pharma since January 2021. With over 25 years of experience as a CEO and CFO in the Life Sciences and technology sectors, Fredrik has effectively sourced venture capital for both private and public companies and established operations in the USA, Europe and Asia.
SE-MEL-AGB 0064 05/2024
© 2024 AGB-Pharma AB. Last updated 11/2024
